Aip-bri
Aip-bri has been studied in 3 papers since 2025: 3 observational studies in people; 3 in the past year. The newest paper, Jun 14, 2026: “Associations of the atherogenic index of plasma and its modified indices with the incidence and progression of cardiometabolic multimorbidity in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3: a prospective cohort study”.
3 papers study it4 findingsUpdated
At a glance
The findings reach people, from one lab or study. 2 independent labs in 1 country.
“AIP-BRI was significantly associated with the progression of CRM diseases in fully adjusted model”
None of its findings points the other way.
- 2 independent labs in 1 country
- Funders: National Natural Science Foundation of China and 1 more
- Humans3
What is aip-bri linked with?
4Studies link aip-bri with 4 measures, among them cardiometabolic multimorbidity, triple cardio-renal-metabolic disease and double cardio-renal-metabolic disease.
Cardiometabolic multimorbidity
upin humans1
1 study
Cardiometabolic multimorbidity
upin humans1
Aip-bri predicts cardiometabolic multimorbidity in humans (added to conventional risk factors).
“with the AIP-body roundness index (AIP-BRI) showing the greatest overall incremental predictive value.”
Humansadded to conventional risk factors
Cardiovascular diabetology
Triple cardio-renal-metabolic disease
upin humans1HR 1.12
1 study
Triple cardio-renal-metabolic disease
upin humans1HR 1.12
Aip-bri is linked with a higher risk of triple cardio-renal-metabolic disease in humans (fully adjusted model; progression from double CRM disease to triple CRM disease) (HR 1.120 (95% CI 1.086–1.155)).
“AIP-BRI was significantly associated with the progression of CRM diseases in fully adjusted model”
Humansfully adjusted model; progression from double CRM disease to triple CRM diseasemedian follow-up 12.7 years
BMC public health
Double cardio-renal-metabolic disease
upin humans1HR 1.18
1 study
Double cardio-renal-metabolic disease
upin humans1HR 1.18
Aip-bri is linked with a higher risk of double cardio-renal-metabolic disease in humans (fully adjusted model; progression from first CRM disease to double CRM disease) (HR 1.180 (95% CI 1.167–1.193)).
“AIP-BRI was significantly associated with the progression of CRM diseases in fully adjusted model”
Humansfully adjusted model; progression from first CRM disease to double CRM diseasemedian follow-up 12.7 years
BMC public health
First cardio-renal-metabolic disease
upin humans1HR 1.248
1 study
First cardio-renal-metabolic disease
upin humans1HR 1.248
Aip-bri is linked with a higher risk of first cardio-renal-metabolic disease in humans (fully adjusted model; baseline to first CRM disease transition) (HR 1.248 (95% CI 1.241–1.255)).
“AIP-BRI was significantly associated with the progression of CRM diseases in fully adjusted model”
Humansfully adjusted model; baseline to first CRM disease transitionmedian follow-up 12.7 years
BMC public health